Cargando…

Experimental Drugs for Neuropathic Pain

BACKGROUND: Neuropathic pain (NP) is an important public health problem and despite recent progress in the un-derstanding, diagnosis, pathophysiological mechanisms and the treatment of NP, many patients remain refractory to pharma-cotherapy. OBJECTIVE: Currently used drugs have limited efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales: Sałat, Kinga, Gryzło, Beata, Kulig, Katarzyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6187752/
https://www.ncbi.nlm.nih.gov/pubmed/29745335
http://dx.doi.org/10.2174/1570159X16666180510151241
_version_ 1783363087071444992
author Sałat, Kinga
Gryzło, Beata
Kulig, Katarzyna
author_facet Sałat, Kinga
Gryzło, Beata
Kulig, Katarzyna
author_sort Sałat, Kinga
collection PubMed
description BACKGROUND: Neuropathic pain (NP) is an important public health problem and despite recent progress in the un-derstanding, diagnosis, pathophysiological mechanisms and the treatment of NP, many patients remain refractory to pharma-cotherapy. OBJECTIVE: Currently used drugs have limited efficacy and dose-limiting adverse effects, and thus there is a substantial need for further development of novel medications for its treatment. Alternatively, drugs approved for use in diseases other than NP can be applied as experimental for NP conditions. This paper covers advances in the field of NP treatment. RESULTS: The prime focus of this paper is on drugs with well-established pharmacological activity whose current therapeutic applications are distinct from NP. These drugs could be a potential novel treatment of NP. Data from preclinical studies and clinical trials on these experimental drugs are presented. The development of advanced methods of genomics enabled to pro-pose new targets for drugs which could be effective in the NP treatment. CONCLUSION: Experimental drugs for NP can be a treatment option which should be tailor-made for each individual on the basis of pain features, previous therapies, associated clinical conditions, recurrence of pain, adverse effects, contraindications and patients’ preferences. At present, there are only some agents which may have potential as novel treatments. Increasing knowledge about mechanisms underlying NP, mechanisms of drug action, as well as available data from preclinical and clin-ical studies make botulinum toxin A, minocycline, ambroxol, statins and PPAR agonists (ATx086001) promising potential future treatment options.
format Online
Article
Text
id pubmed-6187752
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-61877522019-04-01 Experimental Drugs for Neuropathic Pain Sałat, Kinga Gryzło, Beata Kulig, Katarzyna Curr Neuropharmacol Article BACKGROUND: Neuropathic pain (NP) is an important public health problem and despite recent progress in the un-derstanding, diagnosis, pathophysiological mechanisms and the treatment of NP, many patients remain refractory to pharma-cotherapy. OBJECTIVE: Currently used drugs have limited efficacy and dose-limiting adverse effects, and thus there is a substantial need for further development of novel medications for its treatment. Alternatively, drugs approved for use in diseases other than NP can be applied as experimental for NP conditions. This paper covers advances in the field of NP treatment. RESULTS: The prime focus of this paper is on drugs with well-established pharmacological activity whose current therapeutic applications are distinct from NP. These drugs could be a potential novel treatment of NP. Data from preclinical studies and clinical trials on these experimental drugs are presented. The development of advanced methods of genomics enabled to pro-pose new targets for drugs which could be effective in the NP treatment. CONCLUSION: Experimental drugs for NP can be a treatment option which should be tailor-made for each individual on the basis of pain features, previous therapies, associated clinical conditions, recurrence of pain, adverse effects, contraindications and patients’ preferences. At present, there are only some agents which may have potential as novel treatments. Increasing knowledge about mechanisms underlying NP, mechanisms of drug action, as well as available data from preclinical and clin-ical studies make botulinum toxin A, minocycline, ambroxol, statins and PPAR agonists (ATx086001) promising potential future treatment options. Bentham Science Publishers 2018-10 2018-10 /pmc/articles/PMC6187752/ /pubmed/29745335 http://dx.doi.org/10.2174/1570159X16666180510151241 Text en © 2018 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Sałat, Kinga
Gryzło, Beata
Kulig, Katarzyna
Experimental Drugs for Neuropathic Pain
title Experimental Drugs for Neuropathic Pain
title_full Experimental Drugs for Neuropathic Pain
title_fullStr Experimental Drugs for Neuropathic Pain
title_full_unstemmed Experimental Drugs for Neuropathic Pain
title_short Experimental Drugs for Neuropathic Pain
title_sort experimental drugs for neuropathic pain
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6187752/
https://www.ncbi.nlm.nih.gov/pubmed/29745335
http://dx.doi.org/10.2174/1570159X16666180510151241
work_keys_str_mv AT sałatkinga experimentaldrugsforneuropathicpain
AT gryzłobeata experimentaldrugsforneuropathicpain
AT kuligkatarzyna experimentaldrugsforneuropathicpain